Literature DB >> 2243674

Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study.

A J Flach1, R C Stegman, J Graham, L P Kruger.   

Abstract

Prior investigations have reported that topical nonsteroidal anti-inflammatory drug (NSAID) therapy prevents the development of postoperative angiographic signs of angiographic cystoid macular edema (CME). However, these studies include concurrent use of corticosteroids. The current study reports therapeutic efficacy for ketorolac ophthalmic solution (an NSAID) in the prophylaxis of angiographic aphakic CME (ACME) after cataract surgery without concurrent corticosteroids for the first time. Fifty patients with bilateral cataracts were enrolled in this placebo-controlled, paired-comparison, double-masked study. Eleven patients had evidence of angiographic ACME on postoperative day 40. Two of these patients demonstrated bilateral ACME, one patient had ACME in the NSAID-treated eye, and eight patients demonstrated ACME in the placebo-treated eye. This is a statistically significant difference favoring drug treatment. The signs of anterior ocular inflammation were greater in the eyes with ACME. This study suggests prophylactic treatment of ACME may be possible without the risks of concurrent corticosteroid toxicity. In addition, a higher incidence of ACME in black patients (22%) is observed in this study than has been recognized previously.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2243674     DOI: 10.1016/s0161-6420(90)32423-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Macular oedema: the role of soluble mediators.

Authors:  D Kent; S A Vinores; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

Review 2.  Treatment of cystoid macular edema with non-steroidal anti-inflammatory drugs and corticosteroids.

Authors:  T J Wolfensberger; C P Herbort
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

3.  Assessing the effects of ketorolac and acetazolamide on macular thickness by optical coherence tomography following cataract surgery.

Authors:  Ece Turan-Vural; Elvin Halili; Didem Serin
Journal:  Int Ophthalmol       Date:  2014-06       Impact factor: 2.031

Review 4.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

5.  The treatment of chronic uveitic macular oedema.

Authors:  A D Dick
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

Review 6.  The pathogenesis and clinical presentation of macular edema in inflammatory diseases.

Authors:  Y Guex-Crosier
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

7.  Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study.

Authors:  Christoph Hirneiss; Aljoscha S Neubauer; Anselm Kampik; Carl-Ludwig Schönfeld
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

8.  Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.

Authors:  Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 9.  [Treatment of pseudophakic cystoid macular edema].

Authors:  H T Agostini; L L Hansen; N Feltgen
Journal:  Ophthalmologe       Date:  2007-05       Impact factor: 1.059

10.  Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.

Authors:  Alaa E Radwan; Cheryl A Arcinue; Paul Yang; Pichaporn Artornsombudh; Esam M Abu Al-Fadl; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.